Pfizer Stock Price, News & Analysis

Pfizer Inc. (NYSE: PFE) invites investors to join a webcast discussion featuring Bob Smith, Vice President of Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference. The event is scheduled for December 1, 2021, at 5:10 p.m. EST. Interested parties can access the webcast on www.pfizer.com/investors. A transcript and replay will be available within 24 hours of the event's conclusion, accessible for at least 90 days on the same site.

The Pfizer-BioNTech COVID-19 vaccine showed 100% efficacy in a longer-term analysis for adolescents aged 12-15, with no serious safety issues reported. This data supports submissions for full regulatory approval in the U.S. and globally. The analysis, part of a pivotal Phase 3 trial, indicated that 0 symptomatic COVID-19 cases occurred in vaccinated participants compared to 30 in the placebo group. The companies plan to submit this data for regulatory review to expand the vaccine's approval.

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) have received expanded FDA emergency use authorization for the COVID-19 booster dose for individuals 18 and older. The booster, to be administered at least six months post-primary series, aims to sustain high protection against COVID-19 variants, including Delta. Clinical trials indicated a vaccine efficacy of 95% for booster recipients. The companies expect no impact on existing supply agreements. The FDA's decision is crucial as the pandemic continues to evolve.

Pfizer Inc. (NYSE: PFE) announced that the European Commission has approved XELJANZ® (tofacitinib) at 5 mg twice daily for adults with active ankylosing spondylitis (AS) who do not respond adequately to conventional therapies. XELJANZ is the first oral Janus kinase (JAK) inhibitor approved for five indications in the EU. The approval is based on a Phase 3 study involving 269 patients, which demonstrated significant efficacy over placebo (ASAS20: 56.4% vs. 29.4%, p<0.0001). The approval aims to fulfill an unmet medical need for over one million AS patients in the EU.

Cardiff Oncology (Nasdaq: CRDF) announced a $15 million equity investment from Pfizer (NYSE: PFE) to support its clinical programs for KRAS-mutated cancers, including colorectal and pancreatic cancer. Pfizer acquired 2.4 million shares at $6.22 each as part of its Breakthrough Growth Initiative. This collaboration aims to enhance Cardiff's efforts in developing onvansertib, a PLK1 inhibitor, alongside leveraging data from their clinical trials. Pfizer's VP, Adam Schayowitz, is set to join Cardiff's Scientific Advisory Board to further assist in innovative cancer therapies.

Pfizer has announced a supply agreement with the U.S. government for PAXLOVID™ (PF-07321332; ritonavir), pending FDA authorization. The deal includes 10 million treatment courses for $5.29 billion, reflecting a commitment to ensuring equitable access across various income levels. PAXLOVID, a novel oral antiviral designed to combat SARS-CoV-2, showed an 89% reduction in COVID-19-related hospitalization or death in clinical trials. Pfizer is pursuing regulatory approvals globally while investing $1 billion to enhance manufacturing and distribution.

Pfizer Inc. (NYSE: PFE) has completed its acquisition of Trillium Therapeutics, an immuno-oncology company, for $18.50 per share, totaling approximately $2.22 billion. This acquisition enhances Pfizer's oncology portfolio with novel therapies targeting hematological malignancies. Trillium’s lead molecules, TTI-622 and TTI-621, are currently in Phase 1b/2 clinical trials. The deal will result in Trillium's shares being delisted from the Nasdaq and Toronto Stock Exchange. This strategic move aims to leverage Pfizer's resources to accelerate innovative cancer treatments.

Pfizer Inc. (NYSE: PFE) has announced the retirement of Frank D’Amelio, CFO, after nearly 15 years. D’Amelio will assist in the transition as Pfizer conducts an external search for his successor. Mike McDermott, previously EVP Chief Global Supply Officer, has been appointed to the Executive Leadership Team. Under D’Amelio, Pfizer achieved $150 billion in market cap growth and engaged in $200 billion in acquisitions and partnerships. McDermott played a crucial role in ramping up vaccine production during the COVID-19 pandemic.

Pfizer is seeking Emergency Use Authorization (EUA) for its investigational oral antiviral, PAXLOVID™ (PF-07321332; ritonavir), aimed at treating mild to moderate COVID-19 in high-risk patients. The request is based on an interim analysis from the Phase 2/3 EPIC-HR study, showing an 89% reduction in COVID-19-related hospitalizations or deaths compared to placebo. Rolling submissions for the drug have begun in countries like the UK and Australia, with further submissions planned globally. Pfizer is investing up to $1 billion to support the manufacturing and distribution of PAXLOVID.